Procomcure Biotech is a biopharmaceutical company with a research focus on protein-protein
interactions as a source of innovative products with therapeutic applications. Procomcure
services are based on technologies and procedures that are used daily in the Company's
research.
In its research program the Company develops a drug discovery
platform to identify chemotherapeutics targeting protein-protein interactions.
Procomcure targets heterologous protein-protein interactions in host-pathogen interactions,
specifically infections caused by multi-drug resistant Staphylococcus aureus.
This limited-spectrum approach focusing on severe diseases considers the role of
the host in acquisition and dissemination of infections and development of resistance.
Procomcure uses a method that exploits qualified host-pathogen protein-protein interactions,
using peptides derived from interacting partners, selected for tight binding, as
lead structures for new chemical entities.
In its services program the Company offers arraying services,
in particular of high-density protein arrays and their use in epitope mapping and
antibody screening, services related to analysing protein-protein interactions,
and production of bacterial ORFeomes.
Procomcure Biotech receives funds in the framework of ERA-NET PathoGenoMics, funded by the European Commission to strengthen trans-national genome-based research programmes on human-pathogenic microorganisms. Its ChlamyTrans consortium consists of two commercial and four academic partners to study the pathogenomics of chronic Chlamydia infection. The objective of ChlamyTrans is to use two complementary genome-wide transcriptomics approaches to produce commercially exploitable products for monitoring, treating and ultimately preventing chronic chlamydial infections. Procomcure will produce two chlamydial ORFeomes and will study host-pathogen protein-protein interactions; see gen-au project description (in German).
Procomcure Biotech participates as industrial partner in the Laura-Bassi Centre of Expertise THERAPEP. The Laura-Bassi Centres of Expertise carry out applied basic research at the interface with industry. THERAPEP, led by Dr. Barbara Kofler of Paracelsus Private Medical University in Salzburg, is focused on novel treatments based on pharmacologically active neuropeptides. Procomcure will do ORFeome-based receptor screening for a peptide affecting Candida albicans dimorphism and virulence, and produce peptide derivatives inhibiting hyphal growth of Candida.
